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Abstract
Background: Neuropsychiatric and neurological disorders frequently occur after brain insults associated with neuronal loss. 
Strategies aimed to facilitate neuronal renewal by promoting neurogenesis constitute a promising therapeutic option to 
treat neuronal death-associated disorders. In the adult brain, generation of new neurons occurs physiologically throughout 
the entire life controlled by extracellular molecules coupled to intracellular signaling cascades. Proteins participating in 
these cascades within neurogenic regions constitute potential pharmacological targets to promote neuronal regeneration of 
injured areas of the central nervous system.
Methodology: We have performed in vitro and in vivo approaches to determine neural progenitor cell proliferation to 
understand whether activation of kinases of the protein kinase C family facilitates neurogenesis in the adult brain.
Results: We have demonstrated that protein kinase C activation by phorbol-12-myristate-13-acetate induces neural 
progenitor cell proliferation in vitro. We also show that the nontumorogenic protein kinase C activator prostratin exerts 
a proliferative effect on neural progenitor cells in vitro. This effect can be reverted by addition of the protein kinase C 
inhibitor G06850, demonstrating that the effect of prostratin is mediated by protein kinase C activation. Additionally, we 
show that prostratin treatment in vivo induces proliferation of neural progenitor cells within the dentate gyrus of the 
hippocampus and the subventricular zone. Finally, we describe a library of diterpenes with a 12-deoxyphorbol structure 
similar to that of prostratin that induces a stronger effect than prostratin on neural progenitor cell proliferation both in 
vitro and in vivo.
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Conclusions: This work suggests that protein kinase C activation is a promising strategy to expand the endogenous neural 
progenitor cell population to promote neurogenesis and highlights the potential of 12-deoxyphorbols as pharmaceutical 
agents to facilitate neuronal renewal.
Keywords: 12-deoxyphorbol, prostratin, PKC, neurogenesis, neural progenitor cells
Introduction
Neuropsychiatric and neurodegenerative diseases frequently 
occur after central nervous system (CNS) insults such as stroke 
or traumatic brain injury, characterized by an irreversible neu-
ronal loss, for which there is no adequate treatment at present. 
Among novel treatment approaches, some intend to promote 
neuronal replacement in the injured tissue through the genera-
tion of new neurons from neural stem cells (NSCs). In mammals, 
adult NSCs continuously undergoing physiological neurogene-
sis are located fundamentally in the dentate gyrus of the hip-
pocampus (DG) and the subventricular zone (SVZ). Glial-like 
NSCs within these regions produce multipotent undifferenti-
ated neural progenitor cells (NPCs), which can commit to either 
a neuronal phenotype (through neuroblast and mature neuron 
production), or a glial phenotype, generating either astrocytes 
or oligodendrocytes (Alvarez-Buylla and Garcia-Verdugo, 2002; 
Goldman, 2003). Cells isolated from these areas, and cultured in 
the presence of growth factors such as epidermal growth factor 
(EGF) and/or basic fibroblast growth factor (bFGF or FGF-2), gen-
erate cell aggregates known as neurospheres that contain NPCs, 
which exhibit stem cell properties, including the ability to pro-
liferate, self-renew, and undergo multipotential differentiation, 
generating neurons, astrocytes, and oligodendrocytes (Pastrana 
et al., 2009). Newly generated neurons have been found in brain 
lesions of different origins (Parent et al., 1997; Liu et al., 1998; Jin 
et al., 2001; Luka et al., 2002), some of them resulting from the 
differentiation and maturation of neuroblasts generated in neu-
rogenic regions that had migrated to the injured area and some 
others generated from nearby stem cells activated locally by the 
specific injury. However, the neuroregenerative capacity under 
any of these conditions is very limited (Arvidsson et al., 2002; 
Nakatomi et  al., 2002; Teramoto et  al., 2003); thus, to improve 
neuron replacement within an injured region of the CNS, it is 
necessary to find molecules that activate proliferation and/or 
neuronal differentiation of NPCs and NSCs.
Growth factors like EGF or bFGF promote proliferation and/
or fate determination on NPC pools (Palmer et al., 1995; Doetsch 
et al., 2002) through interaction with receptor tyrosine kinases 
(Ullrich and Schlessinger, 1990; Annenkov, 2014). Receptor tyros-
ine kinases activate intracellular signaling molecules, including 
the family of protein kinase C (PKC) (Annenkov, 2014); several 
members of this PKC family are expressed in neurogenic regions 
(Minami et  al., 2000) and participate in various signaling cas-
cades initiated by growth factors, often determining growth fac-
tor specificity (Corbit et al., 2000). Ten serine-threonine kinases 
constitute the PKC family, which are divided into 3 subfamilies: 
the classical (α, β1, β2, and γ), the novel (δ, ε, θ, and η), and the 
atypical (ζ and λ). Atypical PKCs ζ and λ have been involved in 
NSC to neuron transition (Wang et al., 2012), and several other 
isoforms of PKC are expressed in NPCs isolated from the SVZ of 
newborn rats, among which PKCε seems to be relevant for astro-
cytic differentiation (Steinhart et  al., 2007). It is plausible that 
particular isoforms of PKC may be implicated in other specific 
aspects of adult neurogenesis, like NPC autoregeneration, prolif-
eration, survival, or neuronal differentiation.
Phorbol esters are natural, plant-derived diterpenes known 
to activate novel and classical PKCs by binding to their reg-
ulatory domain, mimicking their physiological activator 
diacylglicerol. The most common phorbol ester is phorbol-
12-myristate-13-acetate (PMA) (Goel et al., 2007), whose major 
drawback is its strong tumor-promoting activity (Deleers and 
Malaisse, 1982). Other naturally occurring phorbols, like pros-
tratin, activate PKC but lack the tumor-promoting activity 
that makes PMA unsuitable for biomedical research (Szallasi 
and Blumberg, 1991b); rather than that, prostratin has shown 
some tumor-supressing activity (Shen et al., 2015), but it is 
best known for its antiviral properties, particularly against 
HIV (see Miana et al., 2015 for a recent review). Prostratin is a 
12-deoxyphorbol first isolated from the plant Pimelea prostrate, 
an endemic New Zealand shrub. Extracts from this and other 
plants containing 12-deoxyphorbols have been historically 
used in Asian medicine. Diterpenes are also abundant in plants 
of the Euphorbiaceae family.
We have studied herein the effect of PKC activation by PMA 
and prostratin on the proliferation and expansion of NPC in 
vitro and in vivo. In addition, we have isolated 6 natural prod-
ucts from Euphorbia resinifera with a 12-deoxyphorbol structure 
similar to that of prostratin, and have comparatively tested this 
library of compounds on NPC proliferation, in an attempt to 
identify whether additional harmless molecules were capable of 
promoting neurogenesis and improving neuronal replacement. 
Our results show that prostratin as well as the related com-
pound ER272 increase NPC proliferation in a PKC-dependent 
manner, both in vivo and in vitro, without affecting the neuronal 
differentiation potential of these NPCs.
Materials and Methods
Reagents
12-Deoxyphorbols were isolated and purified in our labora-
tory. PMA (13-O-acetyl-12-O-tetradecanoylphorbol), prostratin 
(13-O-acetyl-12-deoxyphorbol), and other products unless oth-
erwise indicated were purchased from Sigma-Aldrich (St. Louis, 
MO). The general PKC inhibitor bisindolylmaleimide I, or G06850, 
was from Calbiochem (Millipore, Billerica, MA), used at a final 
concentration of 0.5 µM, and added to the cells 30 minutes before 
addition of PKC activators. Stock solutions of all PKC interact-
ing compounds were prepared in dimethyl sulfoxide (DMSO) and 
prediluted in culture medium before addition to cell cultures.
Plant Material
Latex from Euphorbia resinifera was collected in Tanat, Morocco, 
on December, 2007, by making cuts on stalks and collecting the 
milky secretion. Natural products with 12-deoxyphorbol struc-
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Animal Subjects
Seven-day postnatal CD1 mice were used for NPC isolation from 
the SVZ. Two-month-old adult male mice were used for intrac-
erebroventricular (ICV) injections (in vivo experiments). Animals 
were housed under controlled conditions of temperature (21–
23°C) and light (light:dark 12:12) with free access to food (AO4 
standard maintenance diet; SAFE, Épinay-sur-Orge, France) and 
water. Care and handling of animals were performed according 
to the Guidelines of the European Union Council (2010/63/EU) 
and following the Spanish regulations (65/2012 and RD53/2013) 
for the use of laboratory animals.
SVZ Cell Isolation and Culture
NPCs were obtained from the SVZ of 7-day postnatal mice fol-
lowing the same procedure described in Rabaneda et al. (2008). 
Neurosphere cultures were maintained in defined medium (DM) 
composed of Dulbecco’s modified Eagle’s medium/F12 medium 
(1:1 vol/vol) plus 1 mg/L gentamicin (GIBCO) and the B27 supple-
ment (Invitrogen, Carlsbad, CA). EGF (20 ng/mL) and bFGF (10 ng/
mL; both from PeproTech, Frankfurt, Germany) were added to 
DM for culture expansion, but only bFGF was present during 
experimental settings, unless otherwise indicated.
Neurosphere Assay
To test the effects of our compounds on NPC proliferation, sin-
gle cells from mechanically disaggregated neurospheres were 
plated onto anti-adherent 96-well plates at a density of 20,000 
cells/mL in DM + 10 ng/mL bFGF. 12-Deoxyphorbols and other 
pharmacological agents were added at the time of seeding, and 
all conditions were run in triplicates.
Neurosphere number and size were measured as previously 
described (Rabaneda et al., 2008). Results were obtained from a 
minimum of 3 independent experiments performed with tripli-
cate samples.
Cell Viability Assay
Cells were seeded at a density of 20,000 cells/mL and cultured 
in the absence or presence of specific treatments. Then, cultures 
were disaggregated and mixed with trypan blue [0.04% wt/vol 
in phosphate-buffered saline (PBS)]. Viable cells (those exclud-
ing the trypan blue dye) were counted using a hemocytometer 
under an inverted microscope and were expressed as percent-
age of the total number of cells.
Immunocytochemistry
Neurosphere cells were disaggregated and adhered onto poly-L-
ornithine-coated 8-well glass slide chambers (Lab-Tek) and were 
grown for 48 hours in the presence of bFGF plus specific treat-
ments. Immunodetection was performed as previously described 
(Rabaneda et al., 2008). Antibodies used were rabbit polyclonal anti-
Ki67 (1:1000; Vector) and goat anti-rabbit IgG labeled with Alexa 
Fluor 594 (1:1500; Invitrogen, Carlsbad, CA). Nuclei were counter-
stained for 10 minutes with 0.1 mg/L DAPI (4',6-diamidino-2-phe-
nylindole). Ki67+ cells were counted under a BX60 epifluorescence 
microscope (Olympus, Hamburg, Germany) and expressed as per-
centage of the total number of cells, determined by DAPI staining. 
Quantification was performed in 12 predetermined visual fields/
well and 3 wells/condition. Experiments were repeated a mini-
mum of 3 times and results were expressed as the mean ± SEM.
Cell Death Measurement
Cell death was estimated by counting pyknotic nuclei in the same 
sample preparations and wells used for immunocytochemistry 
(see previous paragraph). Nuclei showing chromatin hypercon-
densation (apoptotic and/or necrotic) were detected by DAPI stain-
ing and expressed as percentage of the total number of nuclei.
Western Blot
Cells from disaggregated neurospheres were resuspended in 
defined medium without any added growth factor and seeded in 
12-well plates (500 000 cells per well and condition). Immediately 
after, cells were pretreated with or without 0.5 µM G06850 for 30 
minutes, then with or without 5  µM prostratin and, 1.5 hours 
later, stimulated with or without 10 ng/mL bFGF. Western blot 
was performed as previously described (Carrasco et  al., 2014). 
Antibodies used were mouse anti-cyclin D1, rabbit anti-cyclin E 
(both at 1:500, Santa Cruz Biotechnologies, Santa Cruz, CA), and 
mouse anti-β-actin as loading control (1:1000, Sigma-Aldrich, 
St Louis, MO). Secondary antibodies were from commercial kits 
(Western Breeze, Invitrogen, Carlsbad, CA). Band density was 
quantified using the ImageJ software.
ICV Administration of Prostratin, ER272, and ER271
Adult male mice weighing 35 to 40 g were anaesthetized with 
ketamine/xylazine and placed on a stereotaxic frame (Kopf 
Instruments). A small trepanation was made 0.8 mm lateral 
to Bregma, where the needle of a 5-µL Hamilton syringe was 
introduced 2.4 mm below the brain surface. Ultra-filtered pros-
tratin, diluted in PBS at a concentration of 5 µM (n = 12), or 
vehicle (n = 12), were injected ipsilaterally into the right lateral 
ventricles. Single injections of 2 µL per brain were performed 
through a time-frame of 10 minutes (corresponding to a total 
of 4 ng of prostratin in the case of prostratin-injected mice); 
afterwards, the Hamilton syringe was left another 5 minutes 
before removal. Animals received daily injections of bromod-
eoxyuridine (BrdU) (120 mg/kg), during 3 days starting the day 
of the surgical procedure. Then, mice were deeply anaesthe-
tized with pentobarbital and perfused with 4% parafolmade-
hyde via ascending aorta. Brains were removed and sliced in 
30-µm serial sections from Bregma 2.1 to -3.8 (Franklin and 
Paxinos, 2007), where the SVZ and hippocampus are contained. 
In a different set of experiments, the same procedure was fol-
lowed except that mice were injected with 2 µL of 1 µM ER272 
(n = 6) or 1 µM ER271 (n = 6), corresponding to a dosage of 0.8 ng 
of each compound per brain, and 6 vehicle-injected mice were 
processed in parallel.
Brain Processing and Immunohistochemistry
Brain removal, processing, and immunohistochemical tech-
niques to detect BrdU and doublecortin (DCX) were performed 
as previously described (Rabaneda et al., 2008). Antibodies used 
were mouse monoclonal anti-BrdU (1:100) from Dako (Hamburg, 
Germany), goat polyclonal anti-DCX (1:200, Santa Cruz Biotech.), 
AlexaFluor 488 donkey anti-mouse and AlexaFluor 594 (both at 
1:1000, from Life Tech.), and biotinylated anti-mouse IgG (1:250) 
from GE Healthcare (Albany, NY).
Quantification of Neurogenesis in Brain Sections
BrdU+ and DCX+ cells were counted in neurogenic areas as pre-
viously described (Rabaneda et al., 2008; Carrasco et al., 2014).
Downloaded from https://academic.oup.com/ijnp/article-abstract/19/1/pyv085/2910089
by guest
on 14 March 2018
4 | International Journal of Neuropsychopharmacology, 2016
Statistical Analysis
When more than one treatment group were compared, statis-
tical analyses were performed using 1-way ANOVA, and when 
normality failed a nonparametric Dunnett’s Method was per-
formed. The Student’s t test was used when only one treatment 
group was compared with the control. Differences were consid-
ered significant at values of P ≤ .05.
Results
PMA-Induced PKC Activation Promotes NPC 
Proliferation
NPCs divide in culture in the presence of growth factors, form-
ing floating cell aggregates known as neurospheres (Bull and 
Bartlett, 2005). The size reached by neurospheres at specific 
time-points is indicative of NPC proliferation, while the num-
ber of new neurospheres formed after subsequent subcultures 
depends on NPC self-renewal capacity (Ramirez-Castillejo et al., 
2006) and survival (Torroglosa et  al., 2007). We used neuro-
sphere assays, in which the size and number of newly formed 
neurospheres is estimated, to test whether PKC activators mod-
ulated NPC proliferation. Experiments were performed in the 
presence of a single growth factor, bFGF, which should not mask 
other mitotic stimuli.
NPC were treated for 72 hours with increasing concentra-
tions of PMA, a potent and widely known PKC activator. PMA 
treatment increased neurosphere size, being 16 nM, the most 
effective concentration (Figure 1 A-B), and this effect was 
reverted by the PKC inhibitor G06850 (Figure 1 C). PMA treatment 
did not modify neurosphere number (Figure 1D). These results 
suggested that PMA promoted NPC proliferation without affect-
ing the viability of neurosphere-forming cells (as neurosphere 
number was unchanged). Neurosphere enlargement in cultures 
treated with 16 nM PMA for 72 hours was accompanied by an 
increment in the total number of cells (Figure 1F), while cell via-
bility was not affected by this concentration of PMA (Figure 1E). 
The proliferative effect of PMA was confirmed by immunocyto-
chemical detection of the cell cycle-marker Ki67 in neurosphere-
derived cells that had been cultured onto an adherent surface 
for 48 hours. In the presence of 16 nM PMA, a 2-fold increase in 
the percentage of Ki67+ cells was observed compared with the 
control, and pretreatment of cultures with the PKC inhibitor 
Figure 1. Effect of phorbol-12-myristate-13-acetate (PMA) on neural progenitor cell (NPC) proliferation in vitro. Proliferation was tested in NPC cultures grown in the 
presence of the growth factor basic fibroblast growth factor (bFGF), unless otherwise indicated. (A) Phase-contrast microscopy images of neurospheres cultured for 72 
hours with or without the protein kinase C (PKC) activator PMA (16 nM) alone or in combination with the PKC inhibitor G06850 (0.5 µM). Scale bar indicates 200 µm. (B) 
Graph shows the effect of increasing concentrations of PMA on neurosphere area after 72 hours of culture. (C) Graph shows neurosphere area after 72 hours of treat-
ment with 16 nM PMA, alone or in combination with 0.5 µM G06850. (D) Effect of increasing concentrations of PMA on neurosphere number, counted after 72 hours 
of culture. (E) Effect of 16 nM PMA on cell viability. (F) Effect of 16 nM PMA on total cell number, counted in a Neubauer chamber after neurosphere disaggregation. (G) 
Fluorescence microscopy images of neurosphere-derived adhered cells grown for 48 h with or without 16 nM PMA and/or the PKC inhibitor G06850 (0.5 μM). Cells were 
immunostained to detect the proliferation marker Ki67 and nuclei were counterstained with 4',6-diamidino-2-phenylindole. Scale bar indicates 100 µm. (H) Quantifica-
tion of Ki67+ cells in cultures described in G. (I) Quantification of pyknotic nuclei in cultures described in G. *P < .05 compared with control in a Student’s t test; #P < .05 
compared with the other groups by 1-way ANOVA.
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G06850 (0.5 µM) abolished the effect of PMA (Figure 1 G-H); these 
results indicate that PMA induced NPC proliferation by activat-
ing PKC. The percentage of pyknotic nuclei was not affected by 
any treatment (Figure 1I).
Effect of Prostratin-Induced PKC Activation on NPC 
Proliferation
In contrast to PMA, other phorbols like prostratin are nontu-
morigenic PKC activators (Szallasi and Blumberg, 1991a, 1991b; 
Szallasi et al., 1992). Thus, the effect of this compound on NPC 
proliferation was tested. In the presence of 1 to 10 µM prostratin, 
neurosphere size increased in a concentration-dependent man-
ner, reaching its maximum at 5 µM (Figure 2A-B). The effect of 
prostratin on neurosphere size occurred through PKC activation, 
because it was reverted by pretreatment with the PKC inhibi-
tor G06850 (Figure  2A, C). In contrast to PMA, PKC activation 
mediated by prostratin increased the number of neurospheres 
formed (Figure  2D); this effect of prostratin could be due to 
increased NPC survival but could also be indicative of a higher 
number of neurosphere-forming cells dividing actively. In fact, 
treatment with prostratin for 72 hours not only increased the 
total cell number present in neurospheres, but it also had a 
protective effect on cell viability (Figure  2E-F). Also, treatment 
of adhered NPC cultures with prostratin induced a 2.5-fold 
increase in the percentage of Ki67+ cells, which was reduced by 
pretreatment with the PKC inhibitor G06850 even below control 
levels (Figure 2G-H), confirming that prostratin-induced activa-
tion of PKC was responsible for this rise in the number of cycling 
cells. No effect of prostratin on pyknotic nuclei percentage was 
observed (data not shown).
A major drawback of manipulating NPC proliferation may 
be the loss of self-renewal capacity, causing stem-cell pool 
exhaustion. In the context of NPC cultures, this would result 
in a decrease on neurosphere number as subcultures go on 
(Ramirez-Castillejo et al., 2006). To rule out that PKC activation 
was affecting NPC self-renewal, we disaggregated neurospheres 






































































































































































Figure 2. Effect of prostratin on neural progenitor cell (NPC) proliferation in vitro. Proliferation was tested in NPC cultures grown in the presence of basic fibroblast 
growth factor (bFGF). (A) Phase-contrast microscopy images of neurospheres cultured for 72 hours in the absence or presence of prostratin (5 µM) with or without addi-
tion of the PKC inhibitor G06850 (0.5 µM). Scale bar indicates 200 µm. (B) Graph shows the effect of increasing concentrations of prostratin on neurosphere area after 
72 hours of culture. (C) Graph shows neurosphere area after 72 hours of treatment with or without 5 µM prostratin and/or 0.5 µM G06850. (D) Effect of prostratin on 
neurosphere number, counted 72 hours after seeding, in the absence or presence of 0.5 µM G06850. (E) Percentage of nonviable cells quantified by trypan blue exclusion 
after 48 hours of culture in the presence or absence of 5 µM prostratin and/or 0.5 µM G06850. (F) Total cell number in NPC cultures after 72 hours in the presence or 
absence of 5 µM prostratin. (G) Fluorescence microscopy images of neurosphere-derived adhered cells grown for 48 hours with or without 5 µM prostratin and/or 0.5 µM 
G06850. Cells were immunostained to detect Ki67, and nuclei were counterstained with 4’,6-diamidino-2-phenylindole. Scale bar indicates 100 µm. (H) Quantification of 
Ki67+ cells in cultures described in G. (I) Effect of a 72-hour pretreatment of NPC with prostratin or PMA (at the indicated concentrations) on the number of secondary 
neurospheres formed in the following 72-hour subculture in the absence of drugs. *P < .05 compared with control in a Student’s t test; #P < .05 compared with the other 
groups in ANOVA for repeated measurements, followed by Student’s t test.
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reseeded single cells at a density of 20 000 cells/mL in fresh con-
trol medium, and cultured them for another 72 hours. The num-
ber of newly formed secondary neurospheres was then counted. 
Surprisingly, pretreatment with 5  µM prostratin increased the 
number of secondary neurospheres formed in the subsequent 
subculture when compared with the control, while no effect of 
PMA was observed (Figure 2I).
The other concern that had to be ruled out was whether 
the capacity of NPCs to differentiate, particularly towards the 
neuronal lineage, would be compromised after treatment with 
PKC activators. To answer this, we disaggregated neurospheres 
that had been treated for 72 hours with prostratin, PMA, or 
none and seeded them onto adherent surfaces in differentiat-
ing conditions for another 72 hours. Then, the neuronal marker 
β-III-tubulin and the glial marker GFAP were detected by immu-
nocytochemistry. Prostratin did not change the percentage of 
cells committed to either neuronal or glial differentiation, while 
only a small effect of PMA on glial differentiation was observed 
(supplementary Figure S1; supplementary Methods).
Prostratin and bFGF Work in Synergy to Upregulate 
Cyclin Expression in NPC Cultures
Growth factors like EGF or bFGF induce NPC proliferation 
through activation of Akt and Erk1/2 signaling pathways (Sung 
et  al., 2007; Torroglosa et  al., 2007), which results in cyclin 
upregulation and cell division (Rabaneda et al., 2008). To study 
whether these mechanisms were involved in the proliferative 
effect of prostratin, a neurosphere assay was performed in the 
absence or presence of the Akt pathway inhibitor LY294002 or 
the Erk1/2 pathway inhibitor UO126. The effect of prostratin on 
neurosphere growth was blocked by UO126 and, remarkably, 
completely abolished by LY294002, indicating that both Akt and 
Erk1/2 are essential downstream effectors of prostratin’s action 
(supplementary Figure S2).
Next, the effect of prostratin treatment on cyclin expres-
sion was analyzed by Western blot. Cyclin E and cyclin D1 were 
upregulated in cultures stimulated by either bFGF or prostratin 
alone, and the combination of both treatments had a synergic 
effect on cyclin upregulation (Figure 3A-B). These results indi-
cated a strong interaction between prostratin and bFGF signal-
ing cascades on cyclin expression induction. But the fact that 
prostratin alone was able to induce the expression of cyclin D1 
and E through PKC activation in growth factor-devoid cultures 
prompted us to consider whether this drug could, by itself, 
increase NPC proliferation. As shown in Figure  3C-D, prostra-
tin alone, in the absence of any added growth factor, was able 
to induce a small but statistically significant increase on neu-
rosphere area despite the fact that NPC are strictly depend-
ent on growth factors for survival and proliferation in culture. 
A synergic effect of prostratin and bFGF on neurosphere growth 
was also evident in agreement with previous observations on 
Figure 3. Effect of prostratin on the expression of cyclins. (A) Representative images of Western blots showing immunodetection of cyclin D1 and E, and beta-actin as 
a loading control. Neural progenitor cell (NPC) cultures were pretreated with or without prostratin (5 μM) and/or the PKC inhibitor G06850 (0.5 μM) for 1.5 hours and 
then stimulated with or without bFGF for 6.5 additional hours. (B) Densitometric quantification of cyclin D1 and cyclin E bands relative to the optical density of the 
corresponding β-actin bands. Results are the mean ± SEM of 3 independent experiments; *P < .05 compared with none (basal levels of cyclins in the absence of basic 
fibroblast growth factor [bFGF] and protein kinase C [PKC]-modulating drugs) in a Student’s t test; #P < .05 compared with the other groups by 1-way ANOVA. (C) Graph 
shows the effect of 5 μM prostratin on both the basal proliferation of NPC in the absence of any added growth factors and on bFGF-induced NPC proliferation after 72 
hours of culture. Prostratin alone significantly increased neurosphere area in the absence of added growth factors; also, a synergistic effect of prostratin and bFGF on 
neurosphere area enlargement was observed. Results are the mean ± SEM of 3 independent experiments; ##P < .01 when compared with control by Student’s t test. (D) 
Representative phase-contrast photomicrographs of the neurosphere culture conditions explained in C. Calibration bar indicates 200 µm.
Downloaded from https://academic.oup.com/ijnp/article-abstract/19/1/pyv085/2910089
by guest
on 14 March 2018
Geribaldi-Doldán et al. | 7
cyclin expression patterns induced by the combination of both 
molecules.
12-Deoxyphorbols Isolated from Euphorbia resinifera 
Exert a More Potent Proliferative Effect Than 
Prostratin
Six 12-deoxyphorbols were isolated from Euphorbia resinif-
era plants, whose chemical structures have been resolved in 
the literature (Figure 4A): ER272 (1) (Schmidt and Evans, 1977); 
ER271 (2) (Schmidt and Evans, 1977; Fatope et  al., 1996); ER14 
(3) (Evans and Schmidt, 1976); ER3 (4) (Popplewell et al., 2010); 
ER2 (5) (Fatope et  al., 1996; Fattorusso et  al., 2002; Popplewell 
et al., 2010); and ER8 (6) (Evans and Schmidt, 1976; Fatope et al., 
1996). The effect of these compounds on NPC proliferation was 
investigated using the neurosphere assay at 1, 5, and 10 µM con-
centrations. We found that all tested compounds increased neu-
rosphere size (Figure 4B-D). Moreover, compounds 1 to 4 were 
able to increase neurosphere size 2-fold when used at 1  µM, 
suggesting these were the most potent PKC activators; how-
ever, higher concentrations decreased neurosphere size, prob-
ably because toxic dosage had been reached, similarly to what 
was observed with 10 µM prostratin. Compound 6 was the least 
potent compound, showing very little effect on neurosphere 
size (Figure  4 D). Regarding compound 5, it was the only one 
to induce a continuous concentration-dependent increment in 
neurosphere size, within the range of 1 to 10  µM (Figure 4 D), 
suggesting that this molecule could be the least toxic, the one 
with the wider therapeutic spectrum, and still reach maximum 
potency when applied at a high-enough concentration.
From these results, a general conclusion inferred is that 
12-deoxyphorbols 1 to 6 promoted NPC proliferation. Four 
compounds (1–4) exerted a more potent effect than prostratin 
on NPC proliferation at the smallest concentration used (1 µM), 
being ER272 the compound exerting the most potent effect 
(Figure 4E). Compounds ER272 and ER271 were next applied at 
lower, nanomolar concentrations. Using the neurosphere assay, 
we observed that concentrations of ER272 spanning from 0.1 to 
1 µM increased neurosphere size to a similar extent, with no 
effect on neurosphere number (Figure 5A-C). Additionally, cell 
viability was improved to a significant extent after 72 hours in 
the presence of 1 µM ER272 (Figure 5D). Immunocytochemical 
experiments on adhered cultures revealed that ER272 induced 
a PKC-dependent 2-fold increase on the percentage of Ki67+ 
cells when used at 1  µM (Figure  5E-F). In summary, ER272 
strongly induced NPC proliferation through PKC activation 
when used at concentrations 5 to 10 times lower than prostra-
tin. The same experimental design was used to test ER271, and 
Figure 4. Effect of 12-deoxyphorbols on neural progenitor cell (NPC) proliferation. (A) Chemical structures of the 12-deoxyphorbols tested on proliferation assays are 
shown. Note that relevant carbon positions have been numbered on the structure of the first compound (ER272 [1]). (B) Phase contrast microscopy images of neuro-
sphere cultures stimulated for 72 hours with basic fibroblast growth factor (bFGF) in the absence and presence of 1 µM 12-deoxyphorbols: ER272 (1), ER271 (2), ER14 
(3), ER3 (4), ER2 (5), and ER8 (6). Calibration bar indicates 200 µm. (C) Effect of different concentrations of ER272 (1), ER271 (2), and ER14 (3) on neurosphere area. *P < .05 
compared with control in a Student's t test. (D) Effect of different concentrations of ER2, ER3, and ER8 on neurosphere area. *P < .05 compared with control in a Student’s 
t test. (E) Comparative effect of prostratin, ER272 (1), ER271 (2), ER14 (3), ER3 (4), ER2 (5), and ER8 (6) tested at 1 µM on neurosphere area. *P < .05 compared with prostratin 
in Student’s t test.
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similar results were obtained, except that a slightly higher con-
centration of the drug (0.25 µM) was needed to exert maximal 
effects (Figure 6A-F). These results suggested that ER272 was 
more effective at activating PKC than ER271, notwithstanding 
that both were more potent than prostratin in promoting NPC 
proliferation.
Prostratin, ER272, and ER271 Did Not Exert a 
Proliferative Effect on a Tumoral Neuroblastoma 
Cell Line
Tumor-promoting phorbols like PMA do not generate tumors by 
themselves but promote tumor growth following exposure to 
a subcarcinogenic dose of a carcinogen (they can thus be des-
ignated as co-carcinogens) (Goel et al., 2007). In an attempt to 
demonstrate that not only prostratin but also other 12-deoxy-
phorbols are nontumorigenic, we tested whether they were able 
to induce proliferation in cancerous cells. The effect of 8 nM 
PMA, 5  µM prostratin, and 1  µM ER272 and ER271 on the pro-
liferation of a neuroblastoma cell line (NB69) was assayed by 
quantifying BrdU incorporation. Unlike PMA, which increased 
2-fold the proliferation of NB69 cells, neither prostratin nor 
ER272 or ER271 induced proliferation when added to NB69 cul-
tures (Figure 6G). These results indicated that 12-deoxyphorbols, 
unlike PMA, exerted their proliferative effect specifically on NPC, 
without affecting neuroblastoma cells.
In Vivo Administration of Prostratin, ER272, or ER271 
Increases NPC Proliferation in Neurogenic Regions 
without Affecting Neuronal Differentiation
To study the relevance of PKC activation on NPC proliferation in 
vivo, we injected prostratin, ER272, and ER271 into adult mouse 
ventricles and studied their effect on neurogenesis. Single ICV 
injections of prostratin (4 ng), ER272 or ER271 (0.8 ng each), or 
vehicle were administered ipsilaterally. Proliferating cells were 
concurrently labeled by BrdU intraperitoneal injections for 3 
days, when brains were fixed and subjected to immunohisto-
chemical detection of BrdU in neurogenic areas. Proliferation 
was quantified as the number of BrdU+ cells found in the SVZ 
and DG, comparing the ipsilateral (injected) side of the brain 
with the contralateral side.
In the SVZ of vehicle-injected mice, a significant increase 
of BrdU+ cells was observed in the ipsilateral side compared 
with the contralateral side, indicating that the injection itself 
induced NPC proliferation (Figure 7A-B, M), probably due to the 
small lesion caused by the procedure. Treatment with pros-
tratin significantly increased the total number of BrdU+ cells 
in both the ipsilateral and contralateral SVZs compared with 
their equivalent in vehicle-injected mice, demonstrating that 
in vivo administration of prostratin increased NPC proliferation 
in the SVZ of adult mice independently of, and further beyond, 
the increase due to procedural tissue damage (Figure 7J-K, M). 
Figure 5. Effect of ER272 (1) on neural progenitor cell (NPC) proliferation. (A) Phase contrast microscopy images of neurosphere cultures stimulated with basic fibroblast 
growth factor (bFGF) in the absence and presence of 1 µM ER272 (1). Calibration bar indicates 200 µm. (B) Effect of different concentrations of ER272 (1) on neurosphere 
area. (C) Effect of different concentrations of ER272 (1) on neurosphere number. (D) Effect of 1 µM ER272 (1) on cell viability assayed by trypan blue exclusion. (E) Fluo-
rescence microscopy images of NPC cultures stimulated with bFGF in the presence and absence of 1 µM ER272 (1) and/or 0.5 µM of the protein kinase C (PKC) inhibitor 
G06850. Cells were immunostained for Ki67 detection and nuclei were counterstained with 4',6-diamidino-2-phenylindole. (F) Quantification of Ki67+ cells in cultures 
described in E. *P < .05 compared with control in a Student’s t test; #P < .05 compared with the other groups by 1-way ANOVA.
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Identically, treatment with ER272 significantly increased the 
number of BrdU+ cells in both the ipsilateral and contralateral 
SVZs (Figure 7D-E, M). However, ER271 injection did not induce a 
statistically significant increase on BrdU+ cells (Figure 7G-H, M).
To address whether in vivo treatment with 12-deoxyphor-
bols would alter the capacity of NPC to differentiate towards 
neuronal lineage, double immunostaining was performed in the 
SVZ of prostratin-, ER272-, and ER271-injected mice to detect the 
early neuronal differentiation marker doublecortin (DCX) within 
BrdU+ cells. As shown in Figure 7N, the percentage of BrdU+ cells 
that coexpressed DCX was not changed by any of these treat-
ments (Figure 7C, F, I, L, N).
In the DG, the injection procedure itself also had an effect 
on BrdU+ cell number (Figure 8A-B, M). Treatment with prostra-
tin further increased NPC proliferation in the ipsilateral DG, but 
not in the contralateral DG (Figure 8J-K, M); the fact that pros-
tratin’s effect did not reach the contralateral DG could be due 
to the wide distance between the site of injection (right lateral 
ventricle) and the DG on the other hemisphere. In contrast, 
ER272 increased the number of BrdU+ cells both in the ipsilat-
eral and the contralateral DG (Figure  8D-E, M), indicating that 
this compound was not only the most potent in vitro, but also 
in vivo. ER271 did not have any effect on DG NPC proliferation 
(Figure 8G-H, M). Finally, none of these treatments affected the 
neurogenic capacity of NPCs within the DG (Figure 8C, F, I, L, N).
Discussion
Neuronal replacement within the adult brain requires the gen-
eration of new neurons from NSCs. This process involves several 
steps: (1) activation and division of NSCs, giving rise to undif-
ferentiated NPCs; (2) dynamic proliferation of NPCs; and (3) dif-
ferentiation of NPC towards the neuronal lineage, which firstly 
requires production of committed neuroblasts that maturate 
into postmitotic neurons. Here, we have explored the capacity 
of new drugs with 12-deoxyphorbol structure to reinforce step 
number 2, that is, to expand NPC populations.
PKC activation promotes proliferation in different cell lines 
by cyclin upregulation (Watanabe et  al., 1992; Dempsey et  al., 
2000; Black and Black, 2012), so we hypothesized that PKC acti-
vators would also promote NPC proliferation. Our results dem-
onstrate that addition of PMA, a prototypical PKC activator, to 
bFGF-stimulated NPC cultures increased proliferation of NPC in 
a PKC-dependent manner.
Phorbol esters activate PKC by acting as diacylglicerol ana-
logs, which help translocate PKC to the cell membrane, where 
Figure 6. Effect of ER271 (2) on neural progenitor cell (NPC) proliferation. (A) Phase contrast microscopy images of neurosphere cultures stimulated with basic fibroblast 
growth factor (bFGF) in the absence and presence of 1 µM ER271 (2). Calibration bar indicates 200 µm. (B) Effect of different concentrations of ER271 (2) on neurosphere 
area. (C) Effect of different concentrations of ER271 (2) on neurosphere number. (D) Effect of 1 µM ER271 (2) on cell viability. (E) Fluorescence microscopy images of NPC 
cultures stimulated with bFGF in the presence and absence of 1 µM ER271 (2) and/or 0.5 µM of the protein kinase C (PKC) inhibitor G06850. Cells were immunostained 
for Ki67 detection and nuclei were counterstained with 4',6-diamidino-2-phenylindole. (F) Quantification of Ki67+ cells in cultures described in E. (G) Bromodeoxyur-
idine (BrdU) incorporation into NB69 human neuroblastoma cells (see supplementary file for procedure details) cultured for 48 hours in the presence of 8 nM phorbol-
12-myristate-13-acetate (PMA), 5 µM prostratin, 1 µM ER271 (2), 1 µM ER272 (1), or none (control). #P < .05 compared with the other groups by 1-way ANOVA.
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enzyme function takes place. However, some phorbol esters 
like PMA are hardly metabolized by the cells, making them 
strong, irreversible drugs that hyperactivate PKC and amplify 
the efficacy of carcinogens (Goel et al., 2007). In contrast, other 
natural phorbols like prostratin are nontumorigenic PKC activa-














































Figure 7. Effect of intracerebroventricular (ICV) administration of 12-deoxyphorbols on subventricular zone (SVZ) neurogenesis. Mice received single unilateral ICV 
injections of prostratin, ER271, ER272, or vehicle, and peritoneal injections of bromodeoxyuridine (BrdU) to label proliferating cells, as described in Methods. Photo-
micrographs show adult mouse brain coronal sections containing the SVZ. Left (A, D, G, J) and middle (B, E, H, K) column photomicrographs show contralateral and 
ipsilateral brain sections, respectively, processed for immunohistochemical detection of BrdU to label proliferating neural progenitor cells (NPCs). Right column photo-
micrographs (C, F, I, L) show ipsilateral sections processed for double immunofluorescence detection of BrdU and doublecortin (DCX), the latter being a cell marker for 
immature newly formed neurons; white arrows point to BrdU/DCX double-labeled cells, which represent a subpopulation of proliferating BrdU+ cells that are already 
committed to neuronal differentiation. (A-C) Vehicle-injected control mice. (D-F) Mice injected with ER272. (G-I) Mice injected with ER271. (J-L) Mice injected with pros-
tratin. (M) Quantification of BrdU+ nuclei within the SVZ of mice that had received ICV injections of the indicated drugs; left bars correspond to the injected side of the 
brain (ipsilateral) and right bars correspond to the non-injected side of the brain (contralateral). (N) Quantification of the percentage of BrdU+ cells that express the early 
neuronal marker DCX; left bars (ipsilateral) and right bars (contralateral). contra, contralateral hemisphere; ipsi, ipsilateral hemisphere; LV, lateral ventricle. Statistics: 
#P < .05 comparing ipsilateral vs contralateral sides in a Student’s t test; *P < .05 when comparing different treatments to control ipsilateral in 1-way ANOVA test; †P < .05 
when comparing different treatments with control contralateral in 1-way ANOVA test. Scale bar = 100 μm.
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Figure 8. Effect of intracerebroventricular (ICV) administration of 12-deoxyphorbols on hippocampal neurogenesis. Mice received single unilateral ICV injections of 
prostratin, ER271, ER272 or vehicle, and peritoneal injections of bromodeoxyuridine (BrdU) to label proliferating cells, as described in Methods. Photomicrographs show 
adult mouse brain coronal sections containing the dentate gyrus of the hippocampus (DG). Left (A, D, G, J) and middle (B, E, H, K) column photomicrographs show con-
tralateral and ipsilateral brain sections, respectively, processed for immunohistochemical detection of BrdU to label proliferating neural progenitor cells (NPCs); black 
arrows point to newly divided cells in the DG. Right column photomicrographs (C, F, I, L) show ipsilateral sections processed for double immunofluorescence detection 
of BrdU and doublecortin (DCX), the latter being a cell marker for immature newly formed neurons; white arrows point to BrdU/DCX double-labeled cells, which rep-
resent a subpopulation of proliferating BrdU+ cells that are already committed to neuronal differentiation. (A-C) Vehicle-injected control mice. (D-F) Mice injected with 
ER272. (G-I) Mice injected with ER271. (J-L) Mice injected with prostratin. (M) Quantification of BrdU+ nuclei within the DG of mice that had received ICV injections of 
the indicated drugs; left bars correspond to the injected side of the brain (ipsilateral) and right bars correspond to the noninjected side of the brain (contralateral). (N) 
Quantification of the percentage of BrdU+ cells that express the early neuronal marker DCX in the ipsilateral (left bars) or contralateral (right bars) side of the injection. 
contra, contralateral hemisphere; ipsi, ipsilateral hemisphere. #P < .05 when comparing ipsilateral vs contralateral sides in a Student’s t test; *P < .05 when comparing 
different treatments with control ipsilateral in 1-way ANOVA test; †P < .05 when comparing different treatments with control contralateral in 1-way ANOVA test. Scale 
bar = 200 μm.
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Prostratin is a 12-deoxyphorbol currently investigated in pre-
clinical trials for its potential use as a pharmacological agent. In 
our hands, prostratin was able to increase NPC proliferation in 
vitro to a similar extent as PMA without affecting the capacity 
of NPCs to differentiate towards the neuronal lineage right after 
treatment (supplementary Figure S1). Furthermore, prostratin 
was able to increase NPC proliferation even in the absence of 
any added growth factor (Figure 3C-D), but when added together 
with bFGF, a synergic effect on NPC proliferation was obtained. 
Prostratin not only increased NPC proliferation but also had a 
positive effect on cell survival, and both effects of prostratin 
disappeared when cells were co-incubated with the PKC inhibi-
tor G06850 (Figure 2). In contrast to PKC activation, addition of 
G06850 alone had no decreasing effect on NPC proliferation 
(Figure 2C-D), suggesting that PKCs are not essential for basal 
bFGF-induced NPC proliferation, but, as demonstrated in here, 
these kinases can be pharmacologically activated to further 
increase NPC division.
We and others have previously shown that postnatal NPC 
proliferation is highly dependent on the activation of Erk1/2 and 
Akt signaling pathways (Sung et al., 2007; Torroglosa et al., 2007). 
Growth factors like EGF or bFGF can activate both pathways in 
these NPC, inducing a phospho-Erk1/2-driven upregulation of 
cyclins, like cyclin E, and a phospho-Akt-dependent phospho-
rylation and degradation of cyclin-dependent kinase inhibitors 
like p27 (Torroglosa et  al., 2007; Rabaneda et  al., 2008). Thus, 
the combination of cyclin upregulation and cyclin-dependent 
kinase inhibitor degradation results in cellular division. It has 
been reported that PKC isoforms, some of which are also acti-
vated by growth factors, can as well modulate the activity of 
Erk1/2 and Akt, although the type of modulation seems to differ 
depending on the cellular context and PKC subtypes involved 
(Black and Black, 2012; Kinehara et al., 2013). We have shown that 
Erk1/2 and Akt pathways were involved in prostratin-induced 
NPC proliferation and that both Erk1/2 and Akt are downstream 
effectors of prostratin-activated PKCs. This was inferred, since 
blockade of either pathway with specific inhibitors (UO126 and 
LY294002, respectively) ablated the effect of prostratin (supple-
mentary Figure S2). Prostratin treatment also resulted in a PKC-
dependent upregulation of cyclins D1 and E, both in the absence 
of growth factors and in synergy with bFGF (Figure 3A-B), sug-
gesting an interaction between specific, still unidentified, PKC 
isoforms and proteins involved in the FGFR signaling cascade. 
An effect of prostratin on proliferation and cyclin expression in 
NPC had not been described before.
The effect of prostratin on adult brain neurogenesis was 
also analyzed in vivo. Our results showed that newly formed 
BrdU+ cells increased in both the DG and SVZ of adult mice 
after prostratin ICV administration. Endogenous neurogenesis 
is activated in response to brain damage (Parent et al., 1997; Liu 
et al., 1998; Jin et al., 2002; Nakatomi et al., 2002; Teramoto et al., 
2003), generating NPCs and neuroblasts that eventually migrate 
to the damaged regions. In here, the small injury generated by 
the injections was enough to activate NPC proliferation in both 
the DG and SVZ, and treatment with 4 ng of prostratin increased 
even further the proliferative response to the small injury in 
both neurogenic regions ipsilaterally. The effect of prostratin 
also reached the contralateral SVZ, but not the contralateral DG. 
These results suggest that prostratin might constitute a new 
drug to increase endogenous neurogenesis and facilitate neu-
ronal renewal after brain lesions. In fact, neuronal commitment 
of NPC was not affected in vivo following prostratin administra-
tion (Figures 7N and 8N). The capacity of prostratin or related 
compounds to cross the blood brain barrier has not been tested, 
but given the lipophilicity of 12-deoxyphorbols, they should 
easily cross lipid membranes; this issue will be object of future 
investigations of our group.
Excessive NSC/NPC proliferation may result in NSC pool 
exhaustion. For instance, in Alzheimer’s disease mouse mod-
els, neurogenesis is highly increased at young ages (probably 
as a compensatory mechanism to neuronal damage) which, 
at last, results in neurogenic niche exhaustion at adult ages 
due to NSC depletion (Lopez-Toledano and Shelanski, 2007). 
Pharmacological expansion of NSC/NPC populations could simi-
larly compromise their self-renewal capacity (Ramirez-Castillejo 
et al., 2006). However, we show in here that prostratin and PMA 
clearly have different effects on NPC self-renewal capacity. By 
analyzing the number of primary and secondary neurospheres 
formed we show that prostratin, but not PMA, may, on the long 
run, enhance self-renewal capacity increasing the pool of undif-
ferentiated progenitors. Noteworthy, not all PKC activating drugs 
have the same outcome.
Nontumorigenic PKC activators, such as prostratin, have been 
enrolled as potentially safe drugs (Hecker, 1985). Therefore, we 
screened a library of natural compounds structurally similar to 
prostratin in the hope that new products with a more potent 
effect on neurogenesis than prostratin could be found. We were 
able to detect 2 compounds, ER271 and ER272, which were more 
potent than prostratin at inducing NPC proliferation. The lipo-
philic domain of phorbol esters, largely comprised of the C12/
C13 diacyl moiety, is thought to be responsible for anchoring 
the phorbol-PKC complex to the plasma membrane, an absolute 
requirement for PKC activation. The ability of phorbol analogues 
to membrane-recruit PKC can be gradually decreased or com-
pletely abolished depending on the polarity and dimension of 
substitutions at these positions (Bertolini et al., 2003). There is 
a general agreement that only PKC agonists inducing irrevers-
ible PKC translocation to the cell membrane are endowed with 
tumor-promoting activity (Sanchez-Duffhues et  al., 2011). Like 
prostratin, our selected 12-deoxyphorbols (1–6) from E. resinifera 
have short lipophilic C13 acyl chains and have no substitution 
at C12 (Figure  4A). Therefore, these compounds should not be 
tumor promoters. In relation to this, 12-deoxyphorbols (1–6) were 
assayed for their capacity to induce proliferation in neuroblas-
toma cells. In contrast to PMA, which was able to induce neuro-
blastoma cell proliferation, none of the 12-deoxyphorbols tested 
exerted a proliferative effect on these tumor cells, indicating that 
12-deoxyphorbols, including prostratin and ER272, exerted their 
proliferative effect specifically on NPC, without affecting cancer-
ous cells. Thus, the use of this type of compound in vivo may 
specifically facilitate NPC expansion after a CNS lesion without 
causing undesirable proliferation of other cell types.
ER272 and ER271, the most potent 12-deoxyphorbols in vitro, 
were also analyzed in vivo. Unilateral ICV injections of 0.8 ng of 
ER271 did not significantly increase NPC proliferation in either 
the SVZ or DG, suggesting that this compound may be read-
ily degraded or metabolized when injected in vivo. In contrast, 
unilateral injection of ER272 (0.8 ng) significantly increased 
NPC proliferation in the SVZ and DG of both brain hemispheres 
(Figure 8D-E, M). The largest effect obtained with ER272 in vivo 
is in agreement with its highest potency in vitro but may also 
reflect other pharmacokinetic properties such as half-life in vivo 
or diffusion capacity, since ER272 reached as far as the distant 
contralateral DG. None of these compounds affected the capacity 
of NPCs to differentiate towards neuroblasts (Figures 7N and 8N).
The development of strategies to promote neurogenesis in 
damaged regions may constitute a successful approach to solve 
the clinical problems associated with neuronal loss after brain 
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injury. We show here that activating PKC promotes proliferation 
of NPCs in vitro as well as in vivo. Furthermore, we are describing 
at least 5 new PKC activators, and further characterizing 2 of them, 
among which ER272 exerts the most potent effect. Identifying 
the specific PKC isoform targeted by these compounds is a cru-
cial step to facilitate the development of drugs with a more spe-
cific and potent effect on adult brain neurogenesis.
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